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1. Introduction
Osteoporosis can be divided into two principle strands, clinical osteoporosis and densitometric
osteoporosis. Clinical osteoporosis involves the identification of a fragility fracture and does
not need densitometry for treatment to begin. Densitometric osteoporosis is identified via an
assessment of bone mineral density. Approaches to treatment depend on the global fracture
risk and the outcomes of densitometric tests.
The initial stage of the pharmacological treatment of osteoporosis is to identify the pathology
of the primary condition or to determine whether the loss of bone density is a secondary
symptom of a separate condition. Where secondary osteoporosis is identified, priority is given
to the treatment of the primary condition. The option of pharmacological therapy must only
be contemplated if the risk of fracture is too elevated, given that the intention behind phar‐
macological treatment in osteoporosis is to reduce the fracture risk. Based on World Health
Organization figures, less than half of patients presenting a fragility fracture have been
diagnosed with densitometric osteoporosis [1]. Once a course of medication has begun, long-
term management must address improvements to lifestyle and take aspects of, security, cost,
and compliance into account. As such, it is absolutely necessary to assess and make determi‐
nations on the basis of cost, assessment of cost-efficiency, and the adaptability of patients to
drug security.
2. Antiresorptives
2.1. Calcitonin
Calcitonin binds to osteoclasts and hinders bone resorption. The use of salmon calcitonin has
previously been widespread as a result of its extreme potency in humans, a result of its greater
affinity for the human calcitonin receptor.
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Calcitonin is now no longer a treatment for osteoporosis, having been supplanted by other
treatments. Following a European risk-benefit analysis, the scientific committee of the Europe‐
an Medicines Agency (CHMP) advised that treatments using calcitonin should only be deployed
in short-term scenarios.. Treatments using injectable calcitonin should be confined to the short-
term in Paget's disease, the prevention of acute bone loss as a result of sudden immobiliza‐
tion and hypercalcemia resulting from cancer. In addition to this, calcitonin has been proven to
be effective in treating pain resulting from fractures of the vertebral column. [2-4]
2.2. Hormonal Replacement Therapy (HRT)
HRT is a form of treatment which deploys varying doses of estrogen, sometimes on its own,
sometimes in combination with progestagens. The calculated risk of fracture, based on
principal cohort trials of postmenopausal women treated with HRT over the long term,
indicate an appreciable lowering of the likelihood of both vertebral fracture (RR=0.6; CI 95%:
0.36 to 0.99) and wrist fracture (RR=0.39; CI 95%: 0.24 to 0.64), but a non-significant lowering
of the likelihood of hip fracture (RR=0.64; CI 95%: 0.32 to 1.04). The WHI trial (Women's Health
Initiative), a randomised clinical trial (RCT) that assessed postmenopausal women randomly
assigned to combined HRT (combined equine estrogen 0.625mg daily plus medroxyproges‐
terone 2.5mg daily) or a placebo, recorded, following 5.2 years of treatment, a decrease in hip
fracture risk of 34% (hazard ratio [HR]=0.66; CI 95%: 0.45 to 0.98), in clinical vertebral fractures
of 34% (HR=0.66; CI 95%: 0.44 to 0.98) and in any fracture of 24% (HR=0.76; CI 95%: 0.69 to
0.85) [5,6]. In the same investigation, the cohort taking estrogen on its own demonstrated
comparable outcomes, however the treatment was put on hold as a result of an adverse risk-
benefit ratio. In two meta-analyses of RCT’s, a decrease of 27% (RR=0.73; CI 95%: 0.56 to 0.94)
in non-vertebral fractures and a trend towards a reduction of vertebral fractures (RR=0.66; CI
95%: 0.41 to 1.07) was recorded [7]. Nonetheless, neither the HERS (The Heart and Estrogen +
Progestin Replacement Study) RCT nor the subsequent group, the HERS II study (Hulley et
al., 1998), were able to register a decrease of the risk of hip fractures or of other locations
(RR=1.04; CI 95%: 0.87 to 1.25) in patients with a history of cardiovascular disease [8].
The British National Institute of Health and Clinical Excellence published a meta-analysis of
RCTs on HRT efficacy (with estrogen alone or combined) compared with placebo/non-
treatment in postmenopausal women or those with surgical menopause [9]. The outcomes
were organised according to the location of the fracture and the RCT used as the basis for the
calculation of the relative risk was also identified. The outcomes are outlined in table 1.
Fracture Location Nr of RCTs n RESULTS References
Vertebral fracture 4 RCTs 11,842 RR=0.55; CI 95%: 0.46 to 0.66 [10-13]
Non-vertebral fracture 3 RCTs 11,774 RR=0.73; CI 95%: 0.65 to 0.81 [10, 11,14]
Hip fracture 2 RCTs 11,745 RR=0.63; CI 95%: 0.42 to 0.93 [11,14]
Any type of fracture 3 RCTs 11,556 RR=0.70; CI 95%: 0.63 to 0.78 [14-16]
Table 1. Relative fracture risk in NICE meta-analysis
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2.2.1. Security
2.2.1.1. Vascular illness
A thorough and methodical review of five RCTs looking at HRT with estrogen and two looking
at combined HRT estrogen plus progesterone, failed to display compelling variance in the
occurrence of acute coronary events (including acute myocardial infarction) between the
cohort subject to intervention and the control cohort [7]. A combination of the outcomes of
three studies contrasting estrogenic therapy to a placebo [11, 17] reported an odds ratio (OR)
of 1.34 (IC 95%: 1.07 to 1.68) for cerebral vascular events. The combined outcomes of the studies
that contrasted estrogen plus progesterone combined treatment with a placebo [5, 18],
indicated an elevated risk of ictus (OR=1.28; CI 95%: 1.05 to 1.57) in the cohort subject to
intervention. Out of four thorough and methodical reviews of observational trials looking at
women treated with HRT [19-22], three of these indicated a significant decrease in the global
mortality risk for acute coronary events. A recently published, thorough and methodical
review, that compensated for selection bias of inclusion and analysis, did not reveal any link
between the THS and the incidence, and mortality of acute coronary events [22].
The WHI primary prevention trial indicated a distinct elevation of the risk of acute coronary
events (41%), starting the second year of treatment (29 instances in the treatment cohort,
compared with 21 instances for 10,000 women per year in the general population) [5]. This
elevated risk was greater in non-mortal coronary incidents (RR=1.50; CI 95%: 1.08 to 2.08) than
in the mortal coronary incidents (RR=1.20; CI 95%: 0.58 to 2.50). The RCTs of HRT with
estrogens alone, in both primary and secondary prevention, failed to indicate any positive
impact on cerebrovascular illness [23]. In addition, the WHI study cohort with estrogen
indicated an elevated risk of cerebrovascular incidents.
2.2.1.2. Venous thrombotic events
In a thorough and methodical review, McLean et al. indicated that estrogen patients treated
with estrogen demonstrate an elevated risk of major venous thromboembolic incidents
(OR=1.36; CI 95%: 1.01 to 1.86) compared to the placebo cohort [7]. A further thorough and
methodical review assessing the impact of HRT (estrogen with or without progestagens)
encompassed 12 studies (3 RCTs, 8 case-control studies and 1 cohort study) and indicated an
elevated risk of thromboembolism (RR=2.14; CI 95%: 1.64 to 2.81). This risk was elevated in
the first two years of the therapy and it varied according to the dose [24].
2.2.1.3. Breast cancer
A thorough and methodical review of 4 RCTs proved that patients treated with estrogens alone
have a lower risk of breast cancer (OR=0.79; CI 95%: 0.66 to 0.93) than those treated with the
placebo [7]. On the other hand, patients treated with estrogen and progestin have a higher risk
of breast cancer (OR=1.28; CI 95%: 1.03 to 1.60) than those treated with the placebo [5, 18, 24].
Nonetheless the combined HRT cohort of the WHI study presented an elevated risk of invasive
breast cancer [5]. This elevated risk occurred following the fourth year of treatment (RR=1.26;
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CI 95 %: 1.0 to 1.59), with a propensity to rise in line with the treatment’s longevity (38 instances
compared with 30 for 10,000 women per year).
2.2.1.4. Endometrial cancer
The treatment of estrogen alone elevates the risk of subsequent endometrial hyperplasia and
cancer [25,26]. A meta-analysis including 29 observational studies reported a demonstrable
elevation of the risk of endometrial cancer, with or without combined estrogens (RR=2.3; CI
95%: 2.1 to 2.5) [20]. This risk is directly related to the treatment’s longevity and continues to
be raised for a maximum of 5 years or more following the termination of treatment.
2.2.1.5. Ovarian cancer
Recently published thorough and methodical reviews of observational trials indicate an
elevated incidence of ovarian cancer amongst women undergoing treatment, particularly long-
term therapies (more than 10 years) [28,28]. Two cohort trials of postmenopausal women who
underwent treatment for a period of more than 10 years corroborate this elevated risk of
ovarian cancer (RR=2.2; CI 95%: 1.53 to 3.17), as well as an elevated mortality risk (RR=1.59; CI
95%: 1.13 to 2.25) [29, 30].
We can conclude that HRT is an effective therapy both for postmenopausal osteoporosis and
for the management of fracture risk. Nevertheless, even taking this conclusion into account,
the use of combined HRT is not recommeneded for periods greater than 5 years, given the
possible risk factors linked with treatments using a daily dose equivalent to 50 pg of estradiol.
When HRT treatment is indicated, it should be prescribed at a low dosage (equivalent to
estrogen transdermal patches of 25 mcg), only using higher doses if it is absolutely essential
to do so. Estrogens and progestagens are only advised for the treatment of women with intact
uteri. The level of the progestagen dose should be determined on the basis of the estrogen dose.
In instances where a hysterectomy was carried out as a result of endometrial cancer, HRT
should not involve combined estrogen and progestagens. Continuous combined HRT treat‐
ment should only commence following one whole year of menopause.
2.3. Selective Estrogen Receptor Modulators (SERMs)
Selective estrogen receptor modulators are medications with a selective impact on the estrogen
receptor. They can function as estrogen receptor (ER) agonists in some tissues while in other
tissues functioning as estrogen receptor antagonists. As a result of their selective estrogen-
agonist behaviour within a variety of tissues, SERMs may be indicated as an alternative option
for the prevention or treatment of conditions like osteoporosis, which are the result of a
deficiency of estrogen, where avoiding the negatives effects of estrogens is a priority.
2.3.1. Differences between SERMs
At present there are two forms of SERM, which are distinguished by their chemical structure:
triphenylethylene derivatives, for example tamoxifen and toremifene, and benzothiophene
derivatives, for example raloxifene and bazedoxifene. Tamoxifen and toremifene on the one
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hand are indicated for use in the treatment of breast cancer. Raloxifene on the other hand is
used for the prevention and treatment of osteoporosis and in addition the prevention of breast
cancer. All SERMs have been linked with an elevated occurrence of pulmonary thromboemb‐
olism and with the start of hot flushes, however they also impact in a positive manner on the
lipid profile.
The SERMs vary distinctively with regards to tissue specificity. Bazedoxifene appears to have
a lower impact on the uterus than estradiol jointly with raloxifene in animal experiments as a
result of reduced estrogen receptor alpha agonistic effects.
2.3.2. Raloxifene
Raloxifene acts as estrogen agonist in bone and other systems but not in reproductive tissue.
Many trials have proved the effectiveness of raloxifene for preserving bone in the early
postmenopausal phase. In a meta-analysis of seven studies (four treatment and three preven‐
tion studies) which looked at the impact of raloxifene versus a placebo on bone mineral density,
raloxifene augmented bone mineral density within the lumbar spine following a two year
period of treatment [31]. A trial of 601 women, five years following the menopause, who were
given a daily dose of 30, 60 or 150mg of raloxifene over two years, indicated an augmentation
of their bone mineral density in spine and hip, whereas those subjected to the placebo
presented reduced bone mineral density in the same locations [32]. In contrast with the results
from the placebo, the average alteration in BMD with 60mg of raloxifene was 2.4% in the spine
and 2.4% at the total hip (p<0.001 versus placebo). Postmenopausal women presenting low
bone mass and osteoporosis were monitored over eight years in the study entitled ‘Multiple
Outcomes of Raloxifene Evaluation’ (MORE, n=7,705) and its sister trial entitled ‘Continuing
Outcomes Relevant to Evista’ (CORE, n=4,011) [33]. In relation to fractures, whilst raloxifene
treatment led to a decreased risk of vertebral fracture, it failed to demonstrate a reduced risk
of non-vertebral fractures. Nevertheless, in a meta-analysis of RCTs contrasting the effects of
raloxifene with those of a placebo, raloxifene typically led to a decreased risk of vertebral
fractures in postmenopausal women (OR=0.6; CI 95%: 0.5-0.7).
The results of the MORE trial indicated that, following a raloxifene treatment period of four
years, at 60mg per day, the cumulative relative risk of one or more vertebral fractures was 0.64
(IC 95%: 0.53 - 0.76), compared with treatment using a placebo.
Verus placebo, treatment with 60mg of raloxifene was also linked to a decrease of 65% to 78%
in occurrences of invasive breast cancer and invasive breast cancer with positive estrogen
receptor (both p <0.05).
2.3.2.1. Adverse Effects
The MORE and CORE studies reported a link between raloxifene and an elevated incidence
(1.7 times) of thromboembolism (TE), versus treatment using a placebo (95% CI: 0.93-3.14; risk
difference total of 0.9/1,000 women-years) [34]. In a meta-analysis of nine trials, raloxifene
treatment was linked with an elevated incidence of deep venous thrombosis and pulmonary
embolism (OR=1.5; CI 95%: 1.1-2.1 and OR=1.9; 95% CI: 1.0-3.5, respectively) [35]. The RUTH
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trial (‘Raloxifene Use for The Heart’), which studied 10,101 postmenopausal women with an
average age of 68 and presenting with coronary heart disease, indicated a link between
raloxifene and an elevated incidence of fatal stroke (HR=1.49; 95% CI: 1.00-2.24, a rise in the
absolute risk of 0.7/1,000 women-years) as well as an elevated risk of thromboembolism
(HR=1.44; 95% CI: 1.06-1.95, a rise in the absolute risk of 1.2/1,000 women-years) in comparison
with the placebo results. No elevated risk of myocardial infarction or other coronary events
was indicated in the RUTH trial. Nevertheless, in line with the observations regarding
thromboembolism and pulmonary embolism, the outcomes of a recent review of a sub-cohort
of the trial indicated that age had an impact on the occurrence of coronary events. For women
of 60 years or under, the rate of occurrence of coronary events was distinctly reduced with
raloxifene (50 cases), compared with the placebo group (84 cases; HR=0.59; 95% CI: 0.41 to 0.83,
p=0.003). Raloxifene was also linked with an elevated occurrence of hot flushes, especially
amongst women with recent menopause onset [36].
We can conclude that raloxifene provides an alternative option within osteoporosis therapies
for specific patients. The drug’s profile relating to heart disease and breast cancer is sound but
its links to an elevated risk of venous thrombosis should be taken into account in its use as a
treatment.
2.3.2.2. Bazedoxifene
Bazedoxifene is a third-generation SERM. Some key differences have been demonstrated
between the generations regarding their impact on the uterus and on breast tissue in particular
[37]. The drug was developed with raloxifene as a template and by replacing the benzothio‐
phene core with an indole ring [38].
In a phase II trial of healthy postmenopausal women, oral doses of bazedoxifene 2.5, 5, 10, 20,
30, or 40mg per day were as a rule well-tolerated and did not aggravate the endometrium. In
addition, bazedoxifene 30 and 40 mg resulted in a notably reduced increase in the thickness
of the endometrium and distinctly lowered the occurrence of uterine bleeding versus results
from the placebo. In a two-year phase III trial of postmenopausal women at risk of osteoporosis,
bazedoxifene 10, 20, and 40mg were proven to prevent bone loss and decrease bone turnover
and were linked with a positive endometrial, ovarian, and breast security profile [39, 40].
A phase III, multi-centre, double-blind, randomised, controlled trial was formulated with the
sole purpose of assessing the effectiveness of bazedoxifene in fracture prevention. The trial
looked at 7,492 healthy postmenopausal women presenting with osteoporosis both with or
without prevalent vertebral fractures. The women were randomly assigned to 20 or 40mg per
day of bazedoxifene, 60mg of raloxifene, or to a placebo plus 1200mg of calcium and 400IU of
vitamin D. The primary outcome was the occurrence of new vertebral fractures following a
three-year treatment period. Secondary indicators included clinical vertebral fractures,
worsening of vertebral fractures, non-vertebral fractures, breast cancer incidence, and varia‐
tions in height. Both bazedoxifene 20 and 40mg reduced the occurrence of vertebral fractures
to a similar extent as raloxifene versus the placebo. The occurrence at 36 months of new
vertebral fractures was 2.3%, 2.5%, 2.3%, and 4.1% in the bazedoxifene 20mg, bazedoxifene
40mg, raloxifene 60mg, and placebo cohorts, respectively, with a distinct lowering of the
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relative incidence for new vertebral fractures of 42%, 37%, and 42%, respectively, versus
placebo. There was no overall impact on non-vertebral fractures, with incidence rates of 5.7%
and 5.6% for the bazedoxifene 20 and 40mg cohorts, respectively, versus 5.9% for the raloxifene
cohort and 6.3% for the placebo cohort. Nevertheless, in a later review of women with elevated
fracture risk (poor femoral neck T-score and multiple vertebral fractures, n=1,772), bazedoxi‐
fene 20mg reduced the incidence of non-vertebral fracture by 50% and 44% reduction relative
to the placebo (HR=0.50; 95% CI: 0.28–0.90; p=0.02) and raloxifene 60mg (HR=0.56; 95% CI:
0.31–1.01; p=0.05), respectively [41].
2.3.2.3. Safety
Miller et al. demonstrated that deep venous thromboembolism was uncommon with baze‐
doxifene (0% to 0.6% with varying dosage levels after two years) and similar to the placebo
(0.3%). The rate of occurrence and the intensity of hot flushes were comparable with raloxifene,
but slightly elevated versus placebo [40]. In the trial by Silverman et al., leg cramps (10.9% to
11.7% with varying dosage after three years) and deep venous thromboembolism (0.4% to 0.5%
with varying dosage after three years) were decidedly more prevalent with bazedoxifene
compared with the placebo (8.2% for leg cramps and 0.2% for deep venous thromboembolism),
while fibrocystic breast disease was markedly less frequent. No distinction in risk levels
between bazedoxifene and placebo was noted for myocardial infarction, strokes (ischemic or
hemorraghic), or retinal vein thrombosis [40-43].
We can conclude that bazedoxifene appears to have improved selectivity in contrast with other
SERMs. The impact of bazedoxifene on the skeleton is not dissimilar to raloxifene, and
bazedoxifene may be employed in the same way as raloxifene. The usefulness of bazedoxifene
possibly lies in its risk profile being distinct to that of raloxifene, particularly with regards to
uterine safety, and bazedoxifene may therefore present another option for the prevention and
treatment of osteoporosis.
2.3.3. Lasofoxifene
Lasofoxifene is a powerful third-generation SERM. It has a distinct structure compared to first-
and second-generation SERMs (raloxifene, tamoxifen and clomiphene or idoxifene). Lasofox‐
ifene displays powerful estrogenic and anti-estrogenic activity in vitro and in vivo, targeting
any areas with estrogens receptors, including bone, uterus, breast, blood vessels, and liver.
Lasofoxifene has been analysed in postmenopausal women with regards to the prevention and
treatment of osteoporosis. Security and tolerance levels of lasofoxifene is similar to that of
raloxifene, however nonadherence rates as a result of adverse events are greater with lasofox‐
ifene. Despite these indications, results demonstrate that lasofoxifene treatment may lead to
greater endometrial thickness versus the placebo, despite there being no evidence of an
elevated incidence of endometrial hyperplasia or cancer.
The PEARL study, a three-year pivotal fracture study, showed that lasofoxifene elevated
lumbar spine and femoral neck BMD by approximately 3%. Furthermore, vertebral fractures
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saw a decrease of 42%, and non-vertebral fractures of 27%, with a decrease in markers of bone
turnover. Nevertheless, lasofoxifene did not reduce the risk of hip fractures [43].
2.4. Bisphosphonates
2.4.1. Analysis and mode of action
Bisphosphonates are a member of a class of antiresorptive agents whose antifracture action is
well-documented through randomised controlled studies. There have been no studies to
compare different bisphosphonates, a fact which has prevented the identification of a definite
order of effectiveness for treatment.
Bisphosphonates lower fracture risk as a result of its inhibitory action of osteoclasts, which
enables the osteoblasts to synthesize bone in the resorption spaces and some bone lacunae.
This produces an augmentation in bone mass. However, the bisphosphonates also increase
bone quality, by conserving the bone architecture, as demonstrated in studies which have
analysed the biopsies of treated patients and control subjects.
Bisphosphonates comprise pyrophosphate analogs in which the central oxygen has been
replaced by a carbon atom and two side chains (R1 and R2). Two phosphate chains are vital
to enable the drug to bind to bone and to have an antiresorptive effect.
2.4.2. Etidronate
Etidronate was the original bisphosphonate used in osteoporosis therapy. It is no longer used
in current practice. Its greatest asset is most likely its cost. It augments bone mass in the spine
and femur and lowers the risk of vertebral fractures, however it has not demonstrated a
reduction in the incidence of femoral fractures [44,45].
2.4.3. Clodronate
Clodronate has been deployed in postmenopausal osteoporosis therapy in oral and intrave‐
nous treatments. The trials indicate that it reduces the risk of bone loss in the vertebral spine
in comparison to control subjects, and it presents similar results to estrogens after two years.
In a six-year long study, it was also demonstrated to lower the incidence rate of vertebral
fractures. McCloskey et al. carried out a three-year, double-blind, controlled study to observe
the impact of oral clodronate (800mg per day) on fracture rates. In this study, clodronate was
linked with a distinct improvement in the mean lumbar spine and hip BMD. Furthermore, it
significantly lowered the risk of vertebral fracture (relative risk, 0,54; 95% CI, 0,37-0,80;
p<0,0001). Despite these outcomes, subsequent to the introduction of powerful nitrogen
bisphosphonates, the first-generation bisphosphonates have been reduced to a therapy of last
resort [46].
2.4.4. Alendronate (alendronic acid)
Alendronate is one of the most commonly deployed bisphosphonates. It augments vertebral
bone mass approximately 6-8% and 3-6% at the hip in postmenopausal osteoporotic women
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after a three-year treatment. It demonstrates a reduction in vertebral and non-vertebral
fractures of around 50% in this time period. In male osteoporosis, it has demonstrated
improvements in bone mass of 5% after two years of treatment.
Alendronate is given orally, in doses of 70mg/week, fasting with 200 ml of water. The patient
is prohibited from consuming solids or liquids for 30 minutes after treatment and must remain
standing for this time.
The decisive study of alendronate, the FIT (Fracture Intervention Trial), demonstrated that the
incidence of clinical fracture was reduced for the alendronate cohort compared to the control
cohort (139 (13.6%) versus 183 (18.2%); relative hazard=0.72 (0.58-0.90)). The corresponding
risk of hip and wrist fracture for the alendronate cohort when compared to the placebo cohort
were 0.49 (0.23-0.99) and 0.52 (0.31-0.87) [47]. Ensrud et al. provided an assessment of a subset
of FIT subjects who were patients with an elevated risk of fracture. The outcomes of this
analysis demonstrate a decisive 47% lowering of the risk of new vertebral fractures in the
alendronate cohort when set against the control cohort. A number of other papers have been
generated from the FIT study, addressing multiple symptomatic fractures, bone mineral
density, biochemical markers of formation and resorption, fracture prevention in osteopenic
women, impact of alendronate continuation versus discontinuation, and the impact on women
who lost bone over the course of treatment [48-51].
We can conclude that alendronate is a well-tolerated, secure and efficacious treatment method
for postmenopausal osteoporosis, male osteoporosis, and glucocorticoid induced osteoporosis
(GIOP).
2.4.5. Risedronate
This treatment has been proven to improve bone mass in spine and hip and to considerably
lower the incidence of fracture in postmenopausal women. Treatment of postmenopausal
women with osteoporosis with risedronate over a three-year period has produced a reduction
in the risk of vertebral fractures in roughly 50% and non-vertebral fractures in 39% of subjects.
At the hip, the fracture reduction rate is between 40 and 60%. After a five-year period, the
outcomes are comparable. The treatment has demonstrated its anti-fracture efficacy after a six-
month course. In other trials it has been proven that this reduction in risk was still present
following a seven-year period of treatment, and was accompanied by a positive security
profile. One of the principal studies of risedronate [52] looked at 5,445 women aged 70 to 79
years with osteoporosis (T-score at the femoral neck greater than -4 SD below the mean or
lower than -3 plus a non-skeletal risk factor for hip fracture, such as poor gait or a tendency to
fall) and 3,886 women aged at least 80 years with a minimum of one non-skeletal risk factor
for hip fracture or poor BMD at the femoral neck (T-score below -4 or below -3 plus a hip-axis
length of 11.1cm or greater). The subjects were given a treatment at random of either oral
risedronate (2.5 or 5.0mg per day) or a placebo, over a three-year period. The outcomes
indicated that the risk of hip fracture among subjects given risedronate was 2.8%, versus 3.9%
among those given the placebo (relative risk, 0.7; 95% CI, 0.6 to 0.9; p=0.02). In the cohort of
women with osteoporosis (70 to 79 years old), the risk of hip fracture among subjects given
risedronate was 1.9%, versus 3.2% among subjects given the placebo (relative risk, 0.6; 95% CI,
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0.4 to 0.9; p=0.009). In the cohort of subjects chosen principally for non-skeletal risk factors
(those at least 80 years old), the risk of hip fracture was 4.2% for subjects given risedronate and
5.1% for those given the placebo (p=0.35) [52].
To assess the impact on vertebral fracture risk, Reginster et al. carried out a randomised,
double-blind, controlled trial to evaluate the effectiveness and security of risedronate for
reducing the risk of vertebral fractures in postmenopausal women with established osteopo‐
rosis. The trial was carried out at 80 locations in Europe and Australia. In total, 1,226 postme‐
nopausal women with two or more prevalent vertebral fractures were given risedronate 2.5mg
or 5mg per day or a placebo. Whilst the trial was carried out over three years, the 2.5mg cohort
was ended by protocol amendment after two years. Risedronate 5mg lowered the incidence
of new vertebral fractures by 49% over three years in comparison with the placebo (p<0.001).
A distinct decrease of 61% was witnessed over the initial year alone (p=0.001). The decreased
incidence of fracture was comparable in both cohorts after two years. The incidences of non-
vertebral fracture saw a decrease of 33% in relation to the placebo figures over three years
(p=0.06). Risedronate produced a distinct elevation in BMD at the spine and hip within a six-
month period. We can conclude that risedronate 5mg was an efficacious and well-tolerated
treatment for severe postmenopausal osteoporosis, decreasing the risk of vertebral fractures
and increasing bone density in women with chronic osteoporosis [53].
2.4.6. Ibandronate
In trials lasting three years, ibandronate has been proven to decrease the risk of vertebral
fractures (52%) and improve vertebral BMD (6.5%) whilst not having a substantial negative
impact on bone histology. It has also shown to be very efficacious in reducing bone loss in
GIOP (glucocorticoid induced osteoporosis). In women with severe osteoporosis T scores (<-3),
it decreases the risk of non-vertebral fractures up to 69% [54].
Randomised clinical studies such as MOPS (Monthly Oral Pilot Study) or MOBILE (Monthly
Oral Ibandronate in Ladies) have indicated that the ibandronate monthly dosage is just as
efficacious and safe as the daily dosage. Amongst the general population of the pivotal trial
(BONE,  Oral  Ibandronate  Osteoporosis  Vertebral  Fracture  Trial  in  North  America  and
Europe), the likelihood of adverse incidents of the gastrointestinal tract in both the daily
and the intermittent treatment cohorts was similar to the control cohort. Dyspepsia was the
only adverse incident with a marginally greater rate in subjects undergoing therapy with
ibandronate [55].
2.4.7. Zoledronate (zoledronic acid)
Zoledronic acid is a third-generation bisphosphonate. It is roughly as powerful as alendronate,
risedronate and ibandronate, however the application of this drug intravenously prevents any
negative impact and in fact augments the bioavailability, whilst also improving compliance to
100%.
The HORIZON trial (Health Outcomes and Reduced Incidence with Zoledonic Acid Once
Yearly Pivotal Fracture Trial) was a global, multi-centre, double-blind, controlled study of
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postmenopausal women with osteoporosis, whose goal was to demonstrate the increase
efficacy of intravenous zoledronic acid 5mg compared with a control. Subjects presented with
densitometric osteoporosis or densitometric osteopenia with a minimum of 2 mild to moderate
vertebral fractures [56]. Over 7,700 women were involved in the trial and were monitored over
a three-year period; particular scrutiny was made of new fractures, bone remodeling bio‐
chemical markers and densitometric developments. On completion of the trial, subjects that
had been treated with zoledronic acid presented a decrease in the vertebral fracture risk of
70%. The decrease was comparable for the first two years of the trial, varying from 60% to 71%.
In addition, subjects given zoledronate presented a decrease of 41% in hip fracture incidence
and 25% in non-vertebral fracture incidence. The outcomes of bone density and biochemical
bone remodeling markers were also markedly improved for the cohort given zoledronic acid.
Furthermore, bone mineral density was elevated to over 6% in the lumbar spine and total hip,
and to over 5% in the femoral neck. The biochemical markers of bone remodeling, after the
initial transfusion of zoledronic acid, decreased significantly as anticipated, and stayed stable
throughout the remainder of the trial [57].
Many subjects experienced adverse effects over the course of the trial, with a greater occurrence
of these in the zoledronate cohort. This variance was explained by post-infusion syndrome,
which commonly manifested itself 24-48 hours after the zoledronic acid infusion and dissi‐
pated three days after infusion. The syndrome presented with mild fever, myalgias, flu-like
symptoms, headache and/or arthralgias and was dissipated with analgesic, non-steroid anti-
inflammatory drugs or acetaminophen. A few subjects presented with passing renal function
deterioration 9 to 11 days post-infusion, however these instances were of no clinical transcen‐
dence [57].
Perhaps the most significant conclusion in relation to zoledronate therapy is the 28% decrease
in mortality of any cause, which was demonstrated in a cohort of over 2,000 subjects with femur
fracture [56].
We can conclude that zoledronate therapy is extremely efficacious in the reduction of vertebral,
non-vertebral and hip fractures. It reduces mortality, independent of the cause, following a
femur fracture.Moreover, it is a low-risk therapy that avoids the gastrointestinal adverse
events and high nonadherence rates that are commonly encountered with other bisphospho‐
nates, but it should be dispensed and regulated with great caution when treating individuals
with severe renal function impairment.
2.4.8. Safety of bisphosphonates
This class of treatments is usually well-tolerated, provided that they are administered carefully
and that patients adhere to the instructions for their use. Esophageal ulcerations been encoun‐
tered in situations where these treatments are given orally and on a daily basis. They must not
be given to patients with gastric or esophageal ulcerations, or to patients with pyrosis (heart‐
burn) which requires treatment. They must not be administered to pregnant women, or to
individuals with chronic renal impairment. The intravenous bisphosphonates normally give
rise to acute phase reactions with fever, arthromyalgia and flu-like symptoms that commonly
dissipate before the second dosage and which can be mitigated by giving acetaminophen or
Pharmacological Treatment of Osteoporosis
http://dx.doi.org/10.5772/59469
85
ibuprofen concurrently. Hypocalcaemia can present more frequently, so it is advisable to give
calcium and vitamin D concurrently. The renal function has to be regulated both prior to and
following treatments of intravenous bisphosphonates.
The avascular necrosis of the jaw, also called osteonecrosis of the jaw, is a condition which has
concerned many practitioners since Marx identified it for the first time in 2003 and it ought to
be outlined more completely in another chapter [58].
2.4.9. Long-term impact of bisphosphonate therapies: Atypical hip fractures
Research linking atypical fractures of the femur with longstanding treatments of bisphosph‐
onates caused the American Society for Bone and Mineral Research (ASBMR) to launch an
enquiry to consider the important queries raised by the conclusions of this research. The
enquiry’s committee identified both major and minor features of incomplete and complete
atypical femoral fractures and advised that all significant features, including their location in
the subtrochanteric region and femoral shaft, transverse or short oblique orientation, little or
no associated trauma, a medial spike when the fracture is complete, and lack of comminution,
be discernible in order to designate a femoral fracture as atypical. Minor features include the
fracture’s relationship with cortical thickening, a periosteal reaction of the lateral cortex,
prodromal pain, bilaterality, delayed healing, co-morbid conditions, and concurrent drug
usage, including bisphosphonates, other antiresorptive agents, glucocorticoids, and proton
pump inhibitors. On the strength of published and unpublished information and the wide
application of bisphosphonates, the occurrence of atypical femoral fractures linked with
bisphosphonate use for osteoporosis seems to be decidedly uncommon, especially in relation
to the extent to which vertebral, hip, and other fractures are in turn prevented. Moreover, a
causal link between bisphosphonates and atypical fractures has not been demonstrated.
Nevertheless, new investigations infer that the incidence rate increases with longer periods of
therapy, and there is a feeling of unease that a lack of understanding and underreporting could
be hiding the true extent of the issue.
A 2008 trial of 12,777 Swedish women aged 55 years or more with a fracture of the femur was
made public recently. Radiographs of 1,234 of 1,271 women presenting a subtrochanteric or
shaft fracture were analysed. Fifty-nine subjects with atypical fractures were isolated. The
relative and absolute incidence of atypical fractures linked with bisphosphonate treatment was
calculated using a national cohort analysis. The 59 subjects were also subject to a comparison
with 263 control subjects who presented typical subtrochanteric or shaft fractures. The cohort
analysis indicated an age-adjusted proportional risk of atypical fracture of 47.3. The rise in
global risk was 5 instances per 10,000 patient-years. In total, 78% of the fractured patients and
10% of the controls had been given bisphosphonates (multivariable-adjusted odds ratio of
33.3). The incidence level was independent of coexisting ailments. Following cessation of
treatment, the incidence level was reduced by 70% per year from the time of last use (odds
ratio, 0.28; 95% CI, 0.21 to 0.38) [59].
Advances in Osteoporosis86
2.5. Biological agents
Conditions that give rise to bone loss, like osteoporosis, are caused by the imbalance in the
cycles of bone remodeling favouring bone resorption. The receptor activator of the nuclear
factor kB (RANK), and its ligand (RANKL) are critical for the differentiation, activation and
survival of osteoclasts and, as a result are the most simple intermediary in the regulating of
bone remodeling (Burgess et al.1999). It has been proven that the signaling of the RANKL is
inherent to the pathophysiology of many bone loss conditions, such as primary and many
secondary forms of osteoporosis.
2.5.1. Denosumab
Denosumab is a fully human monoclonal IgG2 antibody to RANKL that imitates the effects of
osteoprotegerine (OPG), endogenous inhibitor of RANKL that blocks bone resorption.
Comercial denosumab is sold as a sterile, uncolored solution administered via subcutaneous
injection.
2.5.1.1. Denosumab in human clinical studies
Data is accessible from more than 50 clinical studies in healthy adults and patients with
osteoporosis, bone loss linked with hormone-ablation treatments, rheumatoid arthritis,
advanced cancer (multiple myeloma and advanced malignancies that involve bone and giant
cell tumor of the bone collected since June 2001).
In the Denosumab Fortifies Bone Density (DEFEND) trial, a phase III, randomised, controlled
trial of 332 postmenopausal women with osteopenia sorted by the length of menopause (<5
years, >5 years), denosumab showed a distinctive rise in lumbar BMD (6.5%) at the two-year
point, in relation to the control (-0.6%). It also raised BMD in other sites including total hip,
distal third of the radius, and whole body (p>0.001) in the two cohorts. The rate of side effects
was comparable between the control cohort and the denosumab cohort [60].
In a comparative clinical study, the DECIDE (Determining Efficacy: Comparison of Initiating
Denosumab vs. Alendronate) trial of 1,189 postmenopausal women with low BMD (T-score: ≤-2
SD), subjects were randomly allocated 1:1 to two groups, one to be given subcutaneous
denosumab (60mg per 6 months) plus an oral alendronate placebo weekly or oral alendronate
weekly (70mg) plus a subcutaneous denosumab placebo injection every 6 months. Denosumab
raised total hip BMD in relation to alendronate (3.5% versus 2.5%, p<0.00001). A more
significant increase in BMD could be witnessed with denosumab than with alendronate in
other locations, as in the trochanter (4.5% vs. 3.5%), distal radius (1.1% versus 0.6%), lumbar
spine (5.3% versus 4.2%) and femoral neck (2.2% versus 1.6%); p<0.0003. The security profile
was comparable for the two cohorts. No subject in the trial developed antibodies in reaction
to denosumab [61].
Another phase III, multi-centre, double-blind trial, named STAND (Study of transitioning from
Alendronate to Denosumab) was carried out to assess the impact of denosumab in subjects who
were undergoing alendronate treatment. Five hundred and four postmenopausal women ≥ 55
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years old with a BMD T-score of <-2.0 and >-4 SD, who were taking weekly oral alendronate
for a minimum of six months, were randomly assigned to the treatment for 44±33 months.
Alterations to BMD and bone biochemical markers were assessed. After a year, the cohort
taking denosumab (and had been given alendronate before the trial) presented a markedly
elevated total hip BMD in comparison with the cohort which continued to take alendronate
(1.9% versus 1.05%; p<0.00012). Markedly elevated BMD readings with denosumab in
comparison with alendronate were also noted after one year at the lumbar spine, femoral neck,
and distal radius (all p<0.0125). The side effects and serious side effects were comparable in
both cohorts [62].
Lastly, the principal phase III study, the FREEDOM (Fracture Reduction Evaluation of Denosumab
in Osteoporosis every 6 Months) study, involved 7,868 postmenopausal women with osteopo‐
rosis and a BMD T-score between <-2.0 and >-4 SD and assessed the effectiveness in fracture
reduction of denosumab. Subjects were given 60mg subcutaneous denosumab or placebo
every six months for three years. Approximately 23% of the subjects had experienced a prior
vertebral fracture. The trial’s retention rate of subjects was 83%. The decrease in relative risk
of fracture was 68% (2.3% versus 7.2%; p<0.0001) for vertebral fractures, 20% (6.5% versus 8.0%)
for non-vertebral fractures and 40% (0.7% versus 1.2%) for hip fractures. In comparison to
patients in the control cohort, patients in the denosumab cohort saw a proportional elevation
of 9.2% in bone mineral density at the lumbar spine and 6.0% at the total hip at three years.
No distinctive dissimilarities were apparent between patients who were given denosumab and
those who were given a placebo in the overall rate of side effects, serious side effects, or
nonadherence to the trial as a result of side effects. No instances of osteonecrosis of the jaw
were found in either cohort during this decisive study (Cummings et al. 2009). Lastly, the
positive effects of denosumab therapy were generally discernible following the first treatment
and remained so over the course of up to eight years of denosumab therapy in an open-ended
extension trial [63].
We can conclude that denosumab provides an extremely efficacious substitute for osteoporosis
therapy through the reduction of bone resorption and the elevation of bone mineral density
via the inhibition of RANKL. A distinct benefit of denosumab is its route of administration
and dosage. A subcutaneous injection every 6 months is comparatively free of discomfort and
improves the therapy retention levels.
3. Anabolic agents
3.1. Fluoride
A series of observations were published indicating a low occurrence of fracture in subjects
residing in locations with elevated fluoride levels. Fluoride was first employed in osteoporosis
therapy in 1961. It was authorised for the prevention of osteoporosis in several European
countried, but was never given authorisation by the American Federal Drug Administration
(FDA) [64,65].
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The outcomes of studies into the impact of fluoride on the reduction of fracture risk are
ambiguous. Some trials have shown a reduction in the risk of vertebral fractures under
monofluorophosphate, or sodium fluoride treatment, whereas other trials, giving patients the
same preparations and dosage, did not. In addition, one meta-analysis extends these investi‐
gations and identifies an elevated fracture risk with increasing dosages after four years [66-68].
As a result, fluoride is not employed in the treatment of osteoporosis any longer.
3.2. Teriparatide (1-34 parathohormone)
Within the range of treatment options available, teriparatide or recombinant human PTH
(1-34), has a significant role to play. It is a member of the group of anabolic bone-forming drugs
rather than the anti-resorptive or catabolic group. It is a catalyst for fresh bone formation by
accelerating bone turnover in favour of formation. Teriparatide therapy improves trabecular
connectivity and cortical bone thickness [69] and augments the mechanical properties of bone
causing a marked reduction in vertebral and non-vertebral fractures in postmenopausal
women with osteoporosis, male osteoporosis and corticosteroid-induced osteoporosis [70]. For
this reason its application is deemed to be suitable mostly for individuals at high risk of fracture
and for those for whom other drugs have been unsuccessful [71].
The original indication for teriparatide first made public was the treatment of established
osteoporosis in postmenopausal women. Amongst the varying trials which have been carried
out on this treatment, the FPT (Fracture Prevention Trial) is the most significant. It assessed
teriparatide at dosages of 20 or 40μg/day in controlled conditions in 1,637 postmenopausal
women with vertebral fractures. Subjects taking teriparatide presented a marked decrease in
the rate of fresh vertebral and non-vertebral fractures. They also experienced elevated lumbar
and femoral neck bone density. Whilst the 40μg/day dose had a greater impact on BMD, the
risk of fracture did not vary to any marked extent between the two dosage levels, while the
higher dosage was less tolerated (11% nonretention due to adverse events with 40μg/day
compared with 6% with 20 μg/day or with the placebo). The dosage of 20μg/day presented a
decreased risk of vertebral fracture of 65% and a decreased risk of non-hip non-vertebral
fracture risk reduction of 35%. This trial was originally supposed to run over a 36-month
period, but it was terminated when subjects had undergone on average 21 months of treatment
for safety reasons following osteosarcomas witnessed in rats during drug toxicity trials [72].
In other trials it transpired nevertheless that this effect presented only in juvenile rats given
with elevated doses of PTH [73]. In addition, no instances of osteosarcomas have been noted
in humans.
A subset of subjects were monitored for a maximum of 18 months following the termination
of the therapy. This subset, which had been given teriparatide, demonstrated an enduring 40%
decrease in vertebral fracture risk at 18 months versus the control sample. These outcomes
indicate that the drug’s positive impact on the rate of non-vertebral fractures continues beyond
the termination of treatment [74].
3.2.1. Combination therapy: Teriparatide plus antiresorptives.
Despite bisphosphonates being the current benchmark for the treatment of osteoporosis,
several studies exist that have assessed whether the combination of teriparatide and BP can
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produce a positive impact. The trials indicate that, if both treatments are given at the same
time, bisphosphonates reduce rather than increase the anabolic action of teriparatide [75].
Combined teriparatide and denosumab, on the other hand, improves spine and hip BMD to a
greater extent than either treatment does when administered in isolation. In the DATA-
HRpQCT study, subjects underwent high-resolution peripheral QCT assessments at the distal
tibia and radius (postmenopausal osteoporotic women randomly assigned to take teriparatide
20μg daily (n=31), denosumab 60mg every 6 months (n=33), or both (n=30) for 12 months). In
the teriparatide cohort, the overall volumetric BMD (vBMD) did not vary at either anatomic
location but was improved in both other cohorts at both locations. The elevated vBMD at the
tibia showed an increase in the combination cohort (3.1±2.2%) compared with either the
denosumab (2.2±1.9%) or teriparatide cohort (-0.3±1.9%) (p<0.02). Cortical vBMD was reduced
by 1.6±1.9% at the tibia and by 0.9±2.8% at the radius in the teriparatide cohort whilst it was
elevated in both other cohorts at both anatomic locations. Tibia cortical vBMD saw greater
increases in the combination cohort (1.5±1.5%) than in the other two cohorts (p<0.04 for both
comparisons). Cortical thickness was not affected in the teriparatide cohort, but was elevated
in the other cohorts. Elevations in cortical thickness at the tibia was more marked in the
combination cohort (5.4±3.9%) than the other cohorts (p<0.01 for both comparisons). In the
teriparatide cohort, radial cortical porosity was raised by 20.9±37.6% and by 5.6±9.9% at the
tibia but was not affected in the other two cohorts. Bone stiffness and failure load, as calculated
through finite element analysis, was not affected in the teriparatide cohort but was elevated
in the other two cohorts at both locations. These results suggest that the application of
denosumab combined with teriparatide has a positive impact on HR-pQCT indices of bone
quality to a greater extent than either treatment in isolation and may be of significant clinical
benefit in the management of postmenopausal osteoporosis [76].
3.2.2. Teriparatide in individuals formerly given antiresorptives
The EUROFORS study was a prospective, open-label, randomised study of 865 postmeno‐
pausal women with established osteoporosis and aimed to assess a variety of consecutive
applications of teriparatide over a two-year period. Subjects were split into several subsets
based on their former therapies. The outcomes of the BMD variations and biochemical markers
of bone formation indicated that the application of teriparatide has a beneficial impact on bone
mass and osteoblast function in postmenopausal women with established osteoporosis
whatever the extent or type of former long-term exposure to antiresorptive treatments has
been.
The length of the antiresorptive treatment and the length of pause in treatment between the
former therapy and the teriparatide had no impact on BMD levels at any anatomic location.
The skeletal reaction at the lumbar spine was comparable among former antiresorptive
treatment cohorts at every point in time over the course of the trial, however subjects who had
previously been given etidronate presented a greater increase, most likely a factor of its poorer
anti-remodeling action. At six months, overall hip and femoral neck BMD showed a marked
reduction in the former alendronate subset, and total hip BMD showed a marked reduction in
the former risedronate subset. Overall hip and femoral neck BMD was statistically reduced
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from baseline in all other subsets at the six-month point. Nevertheless, this short-term
reduction was contradicted over longer-term teriparatide therapy. All subsets demonstrated
a numerically distinctive rise in BMD versus baseline after 18 and 24 months of therapy, and
without variations between the cohorts at any point in the trial [77].
3.2.3. Sequential treatment
In a further non-randomised trial, 59 postmenopausal women with osteoporosis formerly
given raloxifene or alendronate over an 18-36 month period, were treated with teriparatide
over 18 months. Variations in BMD and bone-turnover markers were analysed. Subjects who
had formerly been given alendronate saw a delayed rise in bone-turnover markers with results
more than a third lower than those of subjects who had formerly been given raloxifene. Over
the initial six-month period there were marked variations in the rise in BMD at the lumbar
spine and hip. Subjects formerly given raloxifene saw more significant rises in BMD at the two
sites. After 18 months of therapy marked variations continued in the lumbar spine, with greater
improvement in subjects previously given raloxifene, however the variations in the hip were
not as decisive. This proves that this application of teriparatide augments bone turnover in
subjects formerly given raloxifene or alendronate, and that this improvement comes sooner
and is more significant with the raloxifene pretreatment cohort [78].
3.2.4. Corticosteroid-induced osteoporosis and male osteoporosis
Studies have also been published which demonstrate the effectiveness of teriparatide in the
management of GIOP. In a randomised, double-blind study, 428 subjects both male and female
from 22 to 89 years old, who had been given corticosteroids for a minimum of three months
were randomly assigned to be treated with either alendronate 10mg/day or teriparatide 20μg/
day over an 18 month period. After a year, the overall femur BMD was greater in the teripara‐
tide cohort and on termination of the trial there were fewer vertebral fractures in the teripara‐
tide cohort [79].
Teriparatide has also been employed as a treatment in men with osteoporosis. The trial
analysed results from men with idiopathic or secondary osteoporosis being treated with
teriparatide in comparison with a control group. The trial indicated elevated results, inde‐
pendent of gonadal status and other influential elements in the teriparatide cohort [80].
3.2.5. Adverse Effects
Overall,  teriparatide  (recombinant  human  PTH  (1-34))  injections  are  well-tolerated.  It
disappears from the bloodstream in less than four hours following subcutaneous adminis‐
tration. Injections on a daily basis are required and a passing reddening at the injection site
has been observed. Headache and nausea have been noted in under 10% of patients treated
with a daily dose of 20μg. Mild, early, short-term hypercalcemia can transpire, but severe
hypercalcemia is uncommon. Higher levels of urinary calcium (up 30μg per day) and serum
uric acid concentrations (up 13%) are witnessed, however these do not seem to have clinical
ramifications.
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We can conclude that teriparatide is an appropriate and effective drug for the management of
osteoporosis. It is efficacious in addressing a variety of clinical conditions, e.g. male osteopo‐
rosis or corticosteroid-induced osteoporosis.
3.3. 1-84 Parathormone
Intact PTH (PTH 1-84) has been reported to have a beneficial impact on bone micro-architecture
and to reduce incidence of fresh fractures as a result of its bone-forming mode of action [81].
PTH 1-84 is not procurable any more due to the withdrawal of its marketing licence at the
behest of the regulating authority.
4. Dual action agents
4.1. Strontium ranelate
The possible clinical applications of strontium were revealed in approximately 1940, when
strontium-89 was deployed as an analgesic treatment for bone metastases caused by prostate
cancer [82,83].
In-vitro, strontium ranelate augments collagen and non-collagen protein synthesis through
mature osteoblasts. The bone-forming action has been demonstrated by the higher levels of
replication amongst pre-osteoblastic cells. This catalytic action on the duplication of pre-
osteoblastic cells and the higher levels of collagen and non-collagen proteins have caused
strontium ranelate to be regarded as a dual effect bone agent, because it does not simply reduce
resorption [84]. The principal tool that can determine bone resorption at a molecular level is
the RANK/RNAKL/OPG system outlined above. Solutions of 0.1mM to 2nM of strontium
ranelate reduce the capacity of human osteoblasts to cause osteoclast differentiation, by
reducing expression of mRNA of RANK-L and boosting mRNA expression of OPG, as
reported in the trials carried out by Brennan et al. in 2006 [85, 86].
4.1.1. Impact of Strontium ranelate in fracture reduction
Studies have shown that the chemical properties of strontium ranelate cause the, densitometric
values of subjects given the compound to be greater than the true values. Complex mathe‐
matical formulas exist to cut out the statistical impact of this from the DMO value, however it
is more straightforward and sufficiently accurate to assume instead that half of the DMO
achieved in the first year of therapy with strontium ranelate is a result of elevations in BMD
and the remainder is a result of the basis caused by the heavier strontium measured by the
DXA [87].
Information from the SOTI (Spinal Osteoporosis Therapeutic Intervention) study and the
TROPOS (Treatment of Peripheral Osteoporosis) study looked at 1,649 postmenopausal
subjects (SOTI trial) and 5,091 subjects (TROPOS trial) [88,89]. The initial three-year outcomes
demonstrated a decrease in vertebral fractures of 41% with a NNT of 9. Moreover, an im‐
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provement in BMD of 12.7% was recorded. The decrease in vertebral fractures at the end of
the four- and five-year periods was 33% and 24% respectively. In relation to non-vertebral
fractures, the reduction in the relative incidence of fracture with strontium ranelate was 16%
at the end of the three-year period and 15% at the end of the five-year period. A later assessment
of these results in a subset of 1,977 subjects with high fracture risk (≥74 years old and a T-score
of ≤-2.4) indicated a decrease in the incidence of vertebral fracture of 36% at the end of the
three-year period and 43% at the end of the five-year period [87, 90].
4.1.2. Security
Strontium ranelate was deployed in a widespread manner across Europe up to February 2014,
when the European Medicines Agency (EMA) advised that the use of the drug be limited to
cases which cannot use other treatments approved for osteoporosis, and that subjects with
high risk for ischemic cardiac disorders should be excluded from this treatment option. This
decision was grounded in a study carried out by the Pharmacovigilance Risk Assessment
Committee (PRAC) that highlighted doubts about cardiovascular security which went beyond
the risk, already known, of venous thromboembolism. On the basis of the PRAC analysis, an
elevated incidence of serious cardiac disorders (including myocardial infarction) was pin‐
pointed and steps were put forward to minimize the risk, specifically targeting the highlighted
issue, in April 2013.
5. Overview of current treatments
As set out in this review, there are several treatment options for osteoporosis. Unfortunately
the choices are more restricted in daily clinical practice as treatments have been removed or
their use restricted. Table 2 provides a summary of those treatments currently available to
practitioners.
Table 2. Current available osteoporosis therapies
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6. Future treatment options
6.1. Cathepsine K (CatK) inhibitors
Cathepsin K is expressed in the main in osteoclasts and a variety of other multinucleated cells
including giant foreign body cells and Langhans cells. To a lesser extent it is present in
macrophages, synovial fibroblasts, and fibroblasts at sites of wound repair or inflammation,
chondrocytes, various epithelial cells of the human fetus, adult lung airway epithelium,
thyroid epithelium, and potentially in low levels within smooth muscle cells. When the enzyme
has been synthesised, it is separated into lysosomes and can be introduced into the extracellular
environment. It is introduced particularly into the resorption lacuna below actively resorbing
osteclasts where it is causes the degradation of the collagen type I dominated organic bone
matrix. Thus, in a similar manner to pycnoidisostosis, removal of cathepsin K from osteoclasts
prevents bone resorption. Inhibitors of cathepsin K are reported to have a less significant
impact on osteoclast–osteoblast interaction, causing a lower inhibition of bone formation than
available bisphosphonate antiresorptive drugs. Human cathepsin K inhibitors have been
proven to stop bone loss in ovariectomized mice without reducing the anabolic effeciveness
of parathyroid hormone (PTH) [91].
Whilst no CatK inhibitor is licensed for osteoporosis treatment or prevention at the present
time, trials of three CatK inhibitors for the management of osteoporosis have been published:
balicatib, relacatib, and odanacatib.
6.1.1. Balicatib
Balicatib is extremely selective for CatK in enzyme potency tests but has a reduced selectivity
in living tissue. Clinical trials of balicatib have shown elevated BMD in postmenopausal
women, but the drug was linked with cutaneous adverse effects. The first presentation of the
efficacy of cathepsin K inhibitors on human bone density was witnessed with balicatib. This
study, released by Adami et al. at an ASBMR meeting in 2009 (Denver, CO, USA), was a multi-
centre, randomised, controlled, 12 month, dose-range identifying trial of 675 postmenopausal
subjects with lumbar spine T-score less than 2.0. In the cohort treated with 50mg of balicatib
daily, markers of bone resorption were reduced by over 55% with no reduction in markers of
bone formation (osteocalcin, bone-specific alkaline phosphatase and N-terminal propeptide
of type I collagen). The lumbar spine BMD was elevated 4.46%, that of the total hip was elevated
2.25%. Cutaneous reactions, including pruritus and morphea-like alterations, were observed
in a low number of subjects. In a limited Japanese study, intact PTH levels were demonstrated
to be elevated by 50% with balicatib treatment [92].
6.1.2. Relacatib
Relacatib is a powerful but nonselective inhibitor of cathepsins K, L, V, and S for which no
clinical data in humans has been made public. The use of relacatib with ovariectomized and
control monkeys caused an acute and rapid decrease in bone markers, and the impact of this
lasted for a maximum of 48 hours, according to the dosage administered [93].
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On the basis of the adverse effects, especially the cutaneous reactions, the production of all
cathepsin K inhibitor drugs has been discontinued or put on hold, with the exception of
odanacatib and, at present, ONO 5334
6.1.3. Odanacatib
Odanacatib is a potent, selective inhibitor with an ability to inhibit cathepsin K in osteoclasts
[91].
Two trials have been undertaken to assess the effectiveness and security of odanacatib, a phase
I study to determine the dosage and a phase II study to assess the security and effectiveness.
In the Phase I study a cohort of 49 women was used to assess a weekly dose. Doses of 5mg,
25mg, 50mg, and 100mg were used and 12 subjects were placed in the control cohort. A cohort
of 30 women was created to enable the evaluation of the daily dosage. Doses of 0.5, 2.5, and
10mg were deployed, with six subjects placed in the control cohort. All treatments were given
under fasting conditions. Odanacatib had an extended half-life of between 66 and 93 hours for
all the treatments and dosages assessed. The effectiveness of both weekly and daily dosages
in altering the markers was assessed. The impact was dose-dependant but not in proportion
to the dosage level. Decreases in resorption markers were highest for weekly doses >50mg and
daily doses ≥2.5mg. The greatest suppression was witnessed between days 3 and 5 with the
weekly dose and this level remained elevated until the subsequent treatment [95].
The Phase II trial presented by Cusick et al. at the ASBMR meeting in 2009 (Denver, Co, USA),
was a double-blind, randomised, controlled study lasting one year, with an expected extension
period of two years. It looked at 399 postmenopausal women (postmenopausal (5yr) or
bilateral oophorectomy) aged 45 to 85 years, presenting a T-score <-2 but not less than -3.5 in
any one location. Subjects were assigned to five different cohorts with differing dosage levels:
placebo, 3mg/week, 10mg/week, 25mg/week and 50mg/week. The variations in BMD at the
lumbar spine were analysed and taken as the main outcome. In addition, variations in bone
remodeling, variations in BMD in other locations and side effects were assessed in turn. The
data indicated a elevation in BMD in all locations, which was related to the dose level. The
more significant improvement was achieved with the highest dose. Weekly treatments of 50mg
of odanacatib augmented bone mass by 5.7% in the lumbar spine, 4.1% in the total hip, 4.7%
in the femoral neck, 5.2% in the trochanter and 2.9% in the distal third of the radius at the two-
year point. Resorption markers dropped relative to the dose from the start of the therapy and
stayed lower over the initial six-month period, at which point they increased to a similar level
as those in the control group.
The data from the extension period of the phase II study to the three-year point (reported by
Eisman et al. at the ASBMR meeting 2009 in Denver), looked at 169 women randomly assigned
to weekly doses of odanacatib 50mg or a placebo. In the odanacatib cohort, BMD continued to
rise (lumbar spine 7.5%, total hip 5.5%, femoral neck 5.5% and trochanter 7.4%). The urine NTX
resorption marker was reduced by 50% versus the placebo, while the BSAP (bone specific
alkaline phosphatase) formation marker remained unchanged. At the three-year point,
formation markers had not only not decreased, but had in fact risen by 18% above baseline
values.
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6.1.4. ONO5334
ONO5334 is a new cathepsin K inhibitor. An initial trial has been carried out to assess its
effectiveness and security in the treatment of postmenopausal osteoporosis. This was a year-
long, randomised, double-blind, placebo and active-controlled parallel-group trial carried out
across 13 locations in six European states. The study looked at 285 postmenopausal women
from 55 to 75 years old with osteoporosis. Patients were randomly assigned to one of five
dosage groups: placebo; 50mg twice daily, 100mg once daily, or 300mg once daily of
ONO-5334; or alendronate 70mg once a week. After 12 months of monitoring all ONO-5334
doses and alendronate demonstrated a marked elevation of BMD at the lumbar spine, total
hip (except the 100mg/day cohort), and femoral neck. There was little or no evidence that
ONO-5334 suppressed bone-formation markers versus the alendronate, however the sup‐
pressive action on bone-resorption markers were comparable. There were no security issues
of any clinic consequence. With a marked elevation in BMD, ONO-5334 also heralds a new
mechanism in the treatment of osteoporosis. This new agent increases the range of treatments
available both in the class of cathepsin K inhibitors as the second apparently available agent,
and also across the full range of osteoporosis treatment [94].
We can conclude that Cathepsine K inhibitors are a new class of treatment that adds to the
range of therapies available for the treatment and prevention of fractures, the most hazardous
consequence of osteoporosis. Being able treat this condition at a variety of points along the
resorption pathway is an asset and it provides clinicians with the opportunity to reduce the
risk of fractures more effectively than before.
6.2. Sclerostin
Sclerostin is a protein encoded by the SOST gene [96, 97]. It is identified as an important
inhibitor of osteoblast-mediated bone formation [98, 99]. Loss-of-function mutations in this
gene are linked with sclerosteosis, which results in progressive bone overgrowth and elevated
bone mass and BMD.
A similar condition is van Buchem disease, a less severe form of sclerostosis resulting from by
a deletion downstream of this gene, and leading to reduced sclerostin expression. SOST gene
knockout mice no longer produce sclerostin and have an elevated bone mass, which demon‐
strates the impact this protein has on bone mass and BMD levels. In addition to elevated bone
mass and BMD levels resulting from sclerostin deficiency, it is notable that no fractures have
been reported in patients with either sclerosteosis or van Buchem disease [99, 100].
Sclerostin binds to low-density lipoprotein receptor-related protein (LRP) 5/6 and intercepts
Wnt-signaling, governing bone formation in a negative manner and preventing osteoblast
differentiation, proliferation, and activity [101].
6.2.1. Anti-sclerostin monoclonal antibodies
At the present there are three separate humanized sclerostin antibodies under investigation:
romosozumab (AMGEN & UCB), blozosumab (Eli Lilly) and BPS804 (Novartis). Romosozu‐
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mab is a high affinity immunoglobulin G2 (IgG2) monoclonal antibody. It is produced through
the humanisation of a mouse sclerostin monoclonal antibody that neutralizes sclerostin. The
first-in-human single-dose trial in healthy men and postmenopausal women was carried out
to assess pharmacokinetics, pharmacodynamics, tolerance and security of romosozumab
doses of 0.1, 0.3, 1, 3, 5 or 10mg/kg delivered sub-cutaneously and 1 or 10mg/kg delivered
intravenously. Seventy-two subjects in total took part in the trial and were subsequently
monitored for a maximum of 85 days. The pharmacokinetics of this agent were not relative to
the dosage levels. Dose-related rises in bone formation markers and falls in bone resorption
markers were noted. A small proportion of subjects presented anti-investigational product
bodies however the majority of these were non-neutralizing antibodies. The data indicated
that the agent was well-tolerated [102].
In a phase II, multi-centre, multi-dose, controlled, parallel groups clinical study, 419 postme‐
nopausal women with poor BMD were randomly assigned to the treatment to assess the
effectiveness of romosozumab versus alendronate, teriparatide and a placebo, over a one year
course of therapy. The main outcome was BMD change. All the dosage levels of romosozumab
causes a marked elevation in the BMD at the lumbar spine, femoral neck and total hip together
with a short-term rise in the bone formation markers and a durable fall in the bone resorption
markers [103]. Data from the phase III studies is to be published soon.
A randomised, double-blind, controlled phase II clinical study of blosozumab in postmeno‐
pausal women with poor BMD was recently made available. Subjects were given subcutane‐
ously administered blosozumab 180mg Q4W, 180mg Q2W, 270mg Q2W or equivalent placebo
over a period of one year. In total, 120 women took part. Dosage levels across the range of
blosozumab augmented lumbar spine and total hip BMD. Bone formation markers rose rapidly
during the therapy while bone resorption markers fell at an early point in the therapy and
continued at low level through to the end of the trial [104].
A comparable study was carried out using BPS804 with a similar cohort, however no data is
yet published from this trial.
We can conclude that anti-sclerostin antibodies may be the most efficacious agent in the
treatment of osteoporosis and bone defect related conditions.
7. Conclusion
Over the last decade, new drugs have come forward as potential pharmacological treatments
for osteoporosis. More recent options are part of new classes of agent which present optimised
modes of action, allowing practioners to replace patients’ lost bone mass more quickly and
efficaciously than with older treatments. Nonetheless, it is important to be aware that all drugs
have their appropriate uses and also a wide range of side effects, factors which must be
considered in any clinical decision-making process. Furthermore, it is vital that practitioners
ensure that, as required by the majority of therapies, treatments for osteoporosis are admin‐
istered alongside adjustments in a patient’s lifestyle and/or calcium and vitamin D supple‐
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mentation. New treatments are now coming into use that are likely to enable practitioners to
opt for shorter courses of therapy which result in better outcomes for patients.
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